SCHEMBL14973236

SCHEMBL14973236

CCOC(=O)c1cnn(COCC[Si](C)(C)C)c1CCc1ccc(C(F)(F)F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 4/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
HSP90AA1 P07900 1/20 0.41
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
LMNA P02545 2/20 0.40
FOS P01100 1/20 0.39
JUN P05412 1/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
ADORA3 P0DMS8 1/20 0.37
ADORA2A P29274 1/20 0.37
ADORA2B P29275 1/20 0.37
ADORA1 P30542 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14972977 0.88 PPARA (0.36) MAPTNPC1RAB9AKDM4ELMNA
SCHEMBL14972983 0.85 MAPT (0.49) MAPTNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL14973224 0.84 MAPT (0.48) MAPTNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL14973210 0.80 MAPT (0.50) MAPTNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL2825933 0.78 NPC1 (0.54) MAPTNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL267991 0.76 SMN1; SMN2 (0.48) MAPTNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL2703787 0.74 LMNA (0.42) MAPTNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL30828686 0.74 LMNA (0.42) MAPTNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL24583744 0.73 LMNA (0.42) NPC1RAB9ASMN1; SMN2KDM4EKMT2A
SCHEMBL14972966 0.72 LMNA (0.40) MAPTNPC1RAB9ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2604602-A1 HETEROARYL-PYRAZOLE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-06-19 EP disclosed
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2013-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE GRIN2C, GRIN2B, GRIN3A MAPT 129/4885NPC1 964/4885RAB9A 1090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.